Sotagliflozin in Combination With Optimized Insulin Therapy in Adults With Type 1 Diabetes: The North American inTandem1 Study
Open accessThe DOI matches its Crossref record; 40 of the 41 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Evaluate the efficacy and safety of the dual sodium–glucose cotransporter 1 (SGLT1) and SGLT2 inhibitor sotagliflozin in combination with optimized insulin in type 1 diabetes (T1D). RESEARCH DESIGN AND METHODS: The inTandem1 trial, a double-blind, 52-week phase 3 trial, randomized North American adults with T1D to placebo (n = 268), sotagliflozin 200 mg (n = 263), or sotagliflozin 400 mg (n = 262) after 6 weeks of insulin optimization. The primary end point was HbA1c change from baseline at 24 weeks. HbA1c, weight, and safety were also assessed through 52 weeks. RESULTS: From a mean baseline of 7.57%, placebo-adjusted HbA1c reductions were 0.36% and 0.41% with sotagliflozin 200 and 400 mg, respectively, at 24 weeks and 0.25% and 0.31% at 52 weeks (all P < 0.001). Among patients with a baseline HbA1c ≥7.0%, an HbA1c <7% was achieved by 15.7%, 27.2%, and 40.3% of patients receiving placebo, sotagliflozin 200 mg, and sotagliflozin 400 mg, respectively (P ≤ 0.003 vs. placebo) at 24 weeks. At 52 weeks, mean treatment differences between sotagliflozin 400 mg and placebo were −1.08 mmol/L for fasting plasma glucose, −4.32 kg for weight, and −15.63% for bolus insulin dose and −11.87% for basal insulin dose (all P < 0.001). Diabetes Treatment Satisfaction Questionnaire scores increased significantly by 2.5 points with sotagliflozin versus placebo (P < 0.001) at 24 weeks. Genital mycotic infections and diarrhea occurred more frequently with sotagliflozin. Adjudicated diabetic ketoacidosis (DKA) occurred in 9 (3.4%) and 11 (4.2%) patients receiving sotagliflozin 200 and 400 mg, respectively, and in 1 (0.4%) receiving placebo. Severe hypoglycemia occurred in 17 (6.5%) patients from each sotagliflozin group and 26 (9.7%) patients receiving placebo. CONCLUSIONS: In a 1-year T1D study, sotagliflozin combined with optimized insulin therapy was associated with sustained HbA1c reduction, weight loss, lower insulin dose, fewer episodes of severe hypoglycemia, improved patient-reported outcomes, and more DKA relative to placebo (ClinicalTrials.gov, NCT02384941).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“there is preliminary evidence that in select individuals with type 1 diabetes and excess adiposity, newer pharmacotherapy (i.e., glucagonlike peptide 1 receptor agonists or sodium -glucose cotransporter 2 inhibitors) (195,196) can decrease body weight and improve glycemia, though they are currently not indicated.”
From Nutrition Therapy for Adults With Diabetes or Prediabetes: A Consensus Report (2019) · cites this paper as [195]
Citations
Cites
Assessing Psychosocial Distress in Diabetes
Polonsky, W. H., Fisher, L., Earles, J., Dudl, R. J., Lees, J., Mullan, J., & Jackson, R. A. (2005) · Diabetes Care · doi:10.2337/diacare.28.3.626 · Cited by 1,575 · cited 4×
“At week 24, sotagliflozin-treated patient scores on the DDS2 decreased by 0.7 (20.9 to20.”
BackgroundInfluentialMiller, K. M., Foster, N. C., Beck, R. W., Bergenstal, R. M., DuBose, S. N., DiMeglio, L. A., Maahs, D. M., & Tamborlane, W. V. (2015) · Diabetes Care · doi:10.2337/dc15-0078 · Cited by 1,254
Peters, A. L., Buschur, E. O., Buse, J. B., Cohan, P., Diner, J. C., & Hirsch, I. B. (2015) · Diabetes Care · doi:10.2337/dc15-0843 · Cited by 849 · cited 1×
“has emerged as the major clinical concern around SGLT inhibition in T1D (17,18).”
BackgroundSelf-citationDapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production
Merovci, A., Solis-Herrera, C., Daniele, G., Eldor, R., Fiorentino, T. V., Tripathy, D., Xiong, J., Perez, Z., Norton, L., Abdul-Ghani, M. A., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci70704 · Cited by 795
Bonner, C., Kerr-Conte, J., Gmyr, V., Queniat, G., Moerman, E., Thévenet, J., Beaucamps, C., Delalleau, N., Popescu, I., Malaisse, W. J., et al. (2015) · Nature Medicine · doi:10.1038/nm.3828 · Cited by 670
Outpatient Glycemic Control with a Bionic Pancreas in Type 1 Diabetes
Russell, S. J., El-Khatib, F. H., Sinha, M., Magyar, K. L., McKeon, K., Goergen, L. G., Balliro, C., Hillard, M. A., Nathan, D. M., & Damiano, E. R. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1314474 · Cited by 602 · cited 1×
“have been largely limited to insulin formulation and delivery innovations (1,5,6).”
BackgroundGarg, S. K., Weinzimer, S. A., Tamborlane, W. V., Buckingham, B. A., Bode, B. W., Bailey, T. S., Brazg, R. L., Ilany, J., Slover, R. H., Anderson, S. M., et al. (2017) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2016.0421 · Cited by 585 · cited 1×
“have been largely limited to insulin formulation and delivery innovations (1,5,6).”
BackgroundSelf-citationWeissberg-Benchell, J., Antisdel-Lomaglio, J., & Seshadri, R. (2003) · Diabetes Care · doi:10.2337/diacare.26.4.1079 · Cited by 551
Effects of sotagliflozin added to insulin in patients with type 1 diabetes
Garg, S. K., Henry, R. R., Banks, P., Buse, J. B., Davies, M. J., Fulcher, G. R., Pozzilli, P., Gesty-Palmer, D., Lapuerta, P., Simó, R., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1708337 · Cited by 417 · cited 2×
“incidence of DKA in patients with T1D (14).”
BackgroundSelf-citationAgiostratidou, G., Anhalt, H., Ball, D., Blonde, L., Gourgari, E., Harriman, K. N., Kowalski, A. J., Madden, P., McAuliffe-Fogarty, A. H., McElwee-Malloy, M., et al. (2017) · Diabetes Care · doi:10.2337/dc17-1624 · Cited by 397
Self-citation
Research works printed but not linked: 1
- Bradley, 1994, The Diabetes Treatment Satisfaction Questionnaire: DTSQ, 111
Cited by
Items 101–200 of 234
BOEDER, S. C., Davies, M. J., McGill, J. B., Pratley, R. E., Girard, M., Banks, P. L., Pettus, J., & Garg, S. K. (2024) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2023.0605 · Cited by 16
“2,11,12 In all three trials, fasting BHB data were collected.”
Self-citationRecent developments in adjunct therapies for type 1 diabetes
Timmons, J. G., Littlejohn, L., Boyle, J. G., & Petrie, J. R. (2022) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2022.2159806 · Cited by 17
The nephrological perspective on SGLT-2 inhibitors in type 1 diabetes
Gillard, P., Schnell, O., & Groop, P. (2020) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2020.108462 · Cited by 14
Patel, K. S., & Carbone, A. M. (2019) · Annals of Pharmacotherapy · doi:10.1177/1060028019859323 · Cited by 15
Liu, H., Sridhar, V. S., Perkins, B. A., Rosenstock, J., & Cherney, D. Z. I. (2022) · Current Diabetes Reports · doi:10.1007/s11892-022-01471-2 · Cited by 14
Self-citationEdwards, K., Uruska, A. A., Duda‐Sobczak, A., Zozulińska‐Ziółkiewicz, D., & Lingvay, I. (2023) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/20420188231180987 · Cited by 15
Tornyos, D., Meuer, M., Lukács, R., Abdallaoui, O. E. A. E., Kupó, P., Faludi, R., & Komócsi, A. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.1041200 · Cited by 15
The journey from gene knockout to clinical medicine: telotristat and sotagliflozin
Rendell, M. (2019) · Drug Design Development and Therapy · doi:10.2147/dddt.s144556 · Cited by 14
“InTandem 1 was conducted in the US and Canada.43 InTandem 2 was a European study.44 The inTandem 1 patients treated with sotagliflozin had a mean placebo-corrected A1c reduction from baseline of 0.25% on 200 mg of sotagliflozin taken once daily and a reduction of 0.31% on 400 mg.43 For InTandem 2, the placebo-adjusted…”
BackgroundInfluentialCebada, A. B., Nattero‐Chávez, L., Díaz, S. A., Escobar-Morreale, H. F., & Luque‐Ramírez, M. (2020) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2019.0316 · Cited by 13
Adjunctive Therapies to Optimize Closed-loop Glucose Control
Srinivasan, S., Ekhlaspour, L., & Cengiz, E. (2021) · Journal of Diabetes Science and Technology · doi:10.1177/19322968211032701 · Cited by 14
Popovic, D. S., Karakasis, P., Koufakis, T., Fragakis, N., Παπάνας, Ν., Mitrović, M., Gouveri, E., & Patoulias, D. (2024) · Metabolism · doi:10.1016/j.metabol.2024.155791 · Cited by 15
Pharmacological therapies to address obesity in type 1 diabetes
Casu, A., Bilal, A., & Pratley, R. E. (2020) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000555 · Cited by 16
Zhou, F.-F., Du, N., Zhou, L., Wang, C., Ren, H., & Sun, Q. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.968478 · Cited by 11
Sodium-Glucose Co-Transporter-2 Inhibitors in Type 1 Diabetes: A Scoping Review
Hropot, T., Battelino, T., & Dovč, K. (2022) · Hormone Research in Paediatrics · doi:10.1159/000527653 · Cited by 12
“…participants with a baseline HbA1c ≥7.0% (≥53 mmol/mol), an HbA1c 7% ( 53 mmol/mol) at 24 weeks was achieved by 15.7% of participants receiving placebo, 27.2% of participants receiving sotagliflozin 200 mg, and 40.3% of participants receiving sotagliflozin 400 mg ( p ≤ 0.003 vs. placebo) [35].”
InfluentialSGLT-2 Inhibitors: The Next-generation Treatment for Type 2 Diabetes Mellitus
Lukic, N., Mačvanin, M., Gluvic, Z. M., Rizzo, M., Radak, D. J., Suri, J. S., & Isenović, E. R. (2023) · Current Medicinal Chemistry · doi:10.2174/0109298673251493231011192520 · Cited by 16
Beyond type 2 diabetes: sodium glucose co‐transporter‐inhibition in type 1 diabetes
Biester, T., Kordonouri, O., & Danne, T. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13659 · Cited by 13
“In two 1-year studies (InTandem1: North America, InTandem2: Europe), sotagliflozin showed significant reductions in HbA1c and a reduction in the hypoglycemia rates in T1D adults.(26,27) (Table 1).”
BackgroundSelf-citationMilder, T. Y., STOCKER, S. L., Samocha‐Bonet, D., Day, R. O., & Greenfield, J. R. (2019) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-019-02732-y · Cited by 15
Chen, J.-J., Hsu, C., Hung, C., Liang, C., Su, K., Carvalho, A. F., Stubbs, B., Chen, Y.-W., Chen, T., Lei, W., et al. (2025) · Pharmaceuticals · doi:10.3390/ph18050735 · Cited by 14
Lin, C., Cai, X., Yang, W., Lv, F., Nie, L., & Ji, L. (2020) · BMC Medicine · doi:10.1186/s12916-020-01787-4 · Cited by 12
SGLT2i in Patients with Type 1 Diabetes: Benefits, Risks, and Preventive Strategies
Ma, Y., Zhao, Q., Peng, H., Nalisa, D. L., Shan, P., & Jiang, H. (2023) · Frontiers in Bioscience-Landmark · doi:10.31083/j.fbl2805098 · Cited by 11
“Moreover, patients receiving so-tagliflozin were more satisfied with treatment and experienced less diabetes-related distress [7,8].”
BackgroundMethodErvin, C. M., Joish, V. N., Evans, E., DiBenedetti, D. B., Reaney, M. D., Preblick, R., Castro, R. D. C., Danne, T., Buse, J. B., & Lapuerta, P. (2019) · Clinical Therapeutics · doi:10.1016/j.clinthera.2019.09.003 · Cited by 11
“Participant-reported outcomes (PROs) data from clinical trials 309 and 310 showed increased treatment satisfaction, and reduced stress, as measured by the Diabetes Distress Screening Scale, among patients in the sotagliflozin arms compared with those in the placebo arms.(5,6) To better understand the experiences assoc…”
MethodSelf-citationDanne, T., Joish, V. N., Afonso, M., Banks, P. L., Sawhney, S., Lapuerta, P., Davies, M. J., Buse, J. B., Lin, D., Reaney, M. D., et al. (2020) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2020.0068 · Cited by 12
“8,9 To estimate the proportion of patients at high risk of diabetes distress, randomized patients who completed the DDS2 questionnaire at baseline (i.e., after insulin optimization) were included and deemed as being at either high or low risk.”
Self-citationTeng, R. W., Kurian, M. J., Close, K. L., Buse, J. B., Peters, A. L., & Alexander, C. M. (2020) · Diabetes Spectrum · doi:10.2337/ds20-0038 · Cited by 13
Self-citationRodbard, H. W., Giaccari, A., Cariou, B., Garg, S. K., Davies, M. J., Seth, K., & Sawhney, S. (2021) · Diabetes and Vascular Disease Research · doi:10.1177/1479164121995928 · Cited by 12
Self-citationNardone, M., Kugathasan, L., Sridhar, V. S., Dutta, P., Campbell, D. J. T., Layton, A. T., Perkins, B. A., Barbour, S. J., Lam, T. K. T., Levin, A., et al. (2025) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.0000000641 · Cited by 11
Sotagliflozin: Efficacy, Safety, and Potential Therapeutic Applications in Heart Failure
Long, A. M., & Salvo, M. C. (2023) · Annals of Pharmacotherapy · doi:10.1177/10600280231211179 · Cited by 10
Sotagliflozin: a combined SGLT1/SGLT2 inhibitor to treat diabetes
Rendell, M. (2018) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2018.1537779 · Cited by 10
“discontinuation rates was similar to the Tandem 1 results [23].”
BackgroundResultInfluentialSGLT inhibitors for people with type 1 diabetes
Llano, A., McKay, G., & Fisher, M. (2019) · Practical Diabetes · doi:10.1002/pdi.2222 · Cited by 10
Perkins, B. A., Soleymanlou, N., Rosenstock, J., Skyler, J. S., Laffel, L. M., Liesenfeld, K., Neubacher, D., Riggs, M. M., Johnston, C., Eudy‐Byrne, R. J., et al. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13945 · Cited by 11
Self-citationWang, G., Yan, Y., Zheng, Z., & Zhang, T. (2020) · Bioscience Reports · doi:10.1042/bsr20193800 · Cited by 10
RetractedFerrannini, E., & Rosenstock, J. (2021) · Diabetes Care · doi:10.2337/dc20-0913 · Cited by 11
“In a recent 52-week trial of sotagliflozin (a dual SGLT2/1 inhibitor) in adults with type 1 diabetes (7), the 400mg/day dose was associated with a DKA incidence (IRTx) of 4.”
BackgroundSelf-citationKugathasan, L., Aronson, Y., Sridhar, V. S., Ni, H., Ouimet, J.-P., Limonte, C. P., Sarma, S., & Cherney, D. Z. I. (2025) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2025.2537446 · Cited by 9
Aberer, F., Pieber, T. R., Eckstein, M. L., Sourij, H., & Moser, O. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14061180 · Cited by 12
“The EASE trials for empagliflozin [74], the DEPICT program for dapagliflozin [77], and the inTandem program investigating the double inhibitor treatment of SGLT1 and SGLT2, sotagliflozin [82] have provided evidence for improved glycemic control, reduced insulin doses, and modifying features of the metabolic syndrome (…”
BackgroundMethodA Review of Sotagliflozin: The First Dual SGLT-1/2 Inhibitor
Siddiqui, Z., Rasouli, N., Felder, E., & Frishman, W. H. (2024) · Cardiology in Review · doi:10.1097/crd.0000000000000760 · Cited by 10
Adjunct Antihyperglycemic Agents in Overweight and Obese Adults With Type 1 Diabetes
Isaacs, D. M., Yager, S., Parker, M., Wolfe, L., Luxenburg, J., & Lekic, S. (2018) · Annals of Pharmacotherapy · doi:10.1177/1060028018816728 · Cited by 10
Huang, Y., Jiang, Z., & Wei, Y. (2020) · Endokrynologia Polska · doi:10.5603/ep.a2020.0034 · Cited by 10
Expanding the Use of SGLT2i in Diabetes Beyond Type 2
Giaccari, A. (2023) · Diabetes Care · doi:10.2337/dci23-0065 · Cited by 9
STOUGAARD, E. B., Curovic, V. R., & Hansen, T. W. (2025) · Diabetes Therapy · doi:10.1007/s13300-025-01726-7 · Cited by 11
“Multiple RCTs have evaluated the effects of SGLTis as an adjunct to insulin for glucose con-trol in type 1 diabetes [51–57].”
Hsu, C., Zeng, B., Liang, C., Zeng, B., Hung, C., Stubbs, B., Chen, Y., Lei, W., Chen, J.-J., Chen, P., et al. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26178202 · Cited by 12
Tsur, A., Leibowitz, G., Cohen, M. J., Cahn, A., & Pollack, R. M. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16545 · Cited by 9
Therapeutic applications of carbohydrate-based compounds: a sweet solution for medical advancement
Lalhmangaihzuala, S., Vanlaldinpuia, K., Khiangte, V., Laldinpuii, Z., liana, T., Lalhriatpuia, C., & Pachuau, Z. (2024) · Molecular Diversity · doi:10.1007/s11030-024-10810-2 · Cited by 15
“According to the report, it has been observed that sotagliflozin exhibits the unique characteristics of being a dual SGLT1 and SGLT2 inhibitor, with IC 50 s values of 36 and 1.8 nmol/L [172, 178].”
InfluentialSantos, G. L., dos Santos, C. F., Rocha, G. R., Calmon, M. S., Lemos, F. F. B., Silva, L. G., Luz, M. S., Pinheiro, S. L. R., Botelho, A. C., & de Melo, F. F. (2025) · World Journal of Diabetes · doi:10.4239/wjd.v16.i6.104706 · Cited by 11
Long-term effects of SGLT2 inhibitors on arrhythmias: a systematic review and meta-analysis
Li, P., Chen, W., Chen, R., Zhang, H., Yu, Z., Yan, H., Du, B., & Yang, P. C. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1558367 · Cited by 8
Tseng, P., Zeng, B., Hsu, C.-W., Sun, C., Suen, M., Carvalho, A. F., Stubbs, B., Chen, Y., Chen, T., Lei, W., et al. (2025) · Journal of Hematology & Oncology · doi:10.1186/s13045-025-01750-x · Cited by 9
Khayari, A. E., Hakam, S. M., Malka, G., Rochette, L., & Fatimy, R. E. (2023) · Genes & Diseases · doi:10.1016/j.gendis.2023.101174 · Cited by 8
“27,30 These 52-week phase III trials have reported a statistically signifi-cant correlation between SOTA administration and several positive outcomes.”
BackgroundWang, Y., & Zhou, X. (2024) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-024-03631-7 · Cited by 7
Wang, S., Zhang, Y., Balati, A., Li, B., Dai, L., & Yu, D. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaf016 · Cited by 7
Wang, W., Zhang, L., Pei, X., Pan, Q., & Guo, L. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14092 · Cited by 7
Using adjuvant pharmacotherapy in the treatment of type 1 diabetes
Sjöholm, Å. (2021) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2021.1939679 · Cited by 7
The Changing Landscape of Glycemic Targets: Focus on Continuous Glucose Monitoring
Kushner, P. R., & Kruger, D. F. (2020) · Clinical Diabetes · doi:10.2337/cd19-0093 · Cited by 7
Sodium-Glucose Cotransporter Inhibitors for the Treatment of Type 1 Diabetes Mellitus
Li, N., Chen, R., & Liu, K. (2020) · Clinical Drug Investigation · doi:10.1007/s40261-020-00949-9 · Cited by 6
“BL baseline, BMI body mass index, HbA1c glycosylated hemoglobin, PL placebo, SD standard deviation inTandem1 [42] inTandem2 [43] inTandem3 [41]”
The Evolution of Insulin Administration in Type 1 Diabetes
Pinnaro, C. T., & Tansey, M. (2021) · Journal of Diabetes Mellitus · doi:10.4236/jdm.2021.115021 · Cited by 9
“Results of the EASE, DEPICT, and inTandem trials demonstrated that selective SLGT2 inhibitors are effective adjuncts for glucose lowering therapy in adults with T1D [139–141].”
MethodAn up-to-date evaluation of sotagliflozin for the treatment of type 1 diabetes
Chatzopoulos, G., & Τζιόμαλος, Κ. (2020) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2020.1793961 · Cited by 7
Popovic, D. S., Patoulias, D., Koufakis, T., Karakasis, P., & Παπάνας, Ν. (2024) · Diabetes Therapy · doi:10.1007/s13300-024-01657-9 · Cited by 6
“Adju-dicated DKA occurred in 3.4% and 4.2% of participants receiving sotagliflozin 200 and 400 mg, respectively, and 0.4% receiving placebo, while severe hypoglycemia occurred in 6.5% of individuals from each sotagliflozin group and 9.7% of those receiving placebo, during the InTan-dem1 trial [10].”
InfluentialNoninsulin Therapies in Management of Type 1 Diabetes
Saeed, Z. I., Ambalavanan, J., Rayan, M. N., Patadia, P., & Shah, V. N. (2025) · Endocrine Practice · doi:10.1016/j.eprac.2025.06.027 · Cited by 7
Abdel‐Rahman, S. M., Al-Shiab, R., Shah, E., Güldan, M., Ak, A. B., Yilmaz, Z. Y., Fidan, D. G., Özbek, L., & Kanbay, M. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70506 · Cited by 7
Rajab, A. M., Pearson, S. M., & Ajjan, R. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16332 · Cited by 7
NICE guidance on sotagliflozin for type 1 diabetes
Adler, A., Cronshaw, J., Prescott, C., Patel, S., Donegan, E., & Hayre, J. (2020) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(20)30066-8 · Cited by 5
Sodium-Glucose Transporter Inhibition in Adult and Pediatric Patients with Type 1 Diabetes Mellitus
Vitale, R. J., & Laffel, L. M. (2021) · Advances in Chronic Kidney Disease · doi:10.1053/j.ackd.2021.05.001 · Cited by 7
Borges, R. D. S., Almeida, G. D. O., Alves, V. F. C., Nienkotter, T. F., Bertoli, E. D., & Silva, A. C. S. E. (2023) · Journal of Nephrology · doi:10.1007/s40620-023-01818-2 · Cited by 5
Liu, Y., Yang, S., Jiang, A., Zou, D., Chen, Z., & Su, N. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1453067 · Cited by 9
“Regarding sotagli fl ozin, six of the studies we included were of sotagli fl ozin therapy adjunctive to the treatment T1DM (15 – 17, 19, 20, 30); the overall results suggest that sotagli fl ozin 400 mg is more susceptible to DKA. after the occurrence of DKA, the majority of patients recovered from…”
Várkonyi, T. T., Kupai, K., Kang, H. L., Matusovits, D., Priksz, D., Várkonyi, Á., Lengyel, C., & Pósa, A. (2026) · Antioxidants · doi:10.3390/antiox15050553 · Cited by 4
“During 52 weeks of treatment with sotagliflozin (400 mg), an increased risk of both DKA and hypoglycemia was observed [54,55].”
Curovic, V. R., STOUGAARD, E. B., & Hansen, T. W. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16007 · Cited by 4
“In a post hoc analysis of the inTandem1 and 2 trials, 56,57 including people with type 1 diabetes and eGFR more than 45 mL/min/1.73m 2 , treatment with sotagliflozin was associated with beneficial haemodynamic kidney changes of a similar magnitude as those seen in type 2 diabetes.”
Zhang, Z., Li, Y., Gu, H. F., & Li, N. (2025) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2025.118837 · Cited by 5
The effect of GLP-1 receptor agonist and SGLT2 inhibitor on infection risk: network meta-analysis
Zeng, B.-S., Chen, J.-J., Hsu, C.-W., Hung, C.-M., Zeng, B., Suen, M., Yang, W.-C., Wang, H.-Y., Shiue, Y.-L., Su, K.-P., et al. (2026) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2026.01.014 · Cited by 7
Hamaguchi, M., Hashimoto, Y., Tanaka, T., Hasegawa, G., Ishii, M., Okada, H., Mitsuhashi, K., Kitagawa, N., Ushigome, E., Yamazaki, M., et al. (2021) · Clinical Medicine Insights Endocrinology and Diabetes · doi:10.1177/11795514211040539 · Cited by 4
The anti-hypertensive effects of sodium-glucose cotransporter-2 inhibitors
Kugathasan, L., Dubrofsky, L., Advani, A., & Cherney, D. Z. I. (2022) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2023.2159810 · Cited by 5
“In contrast, the subgroup of patients with elevated BP and T1D in the inTandem1 trial exhibited similar BP-lowering effects compared to the overall population at 12 weeks [34].”
BackgroundResultSGLT 2 inhibitors in Type 1 diabetes: is this the future?
Herring, R. A., & Russell-Jones, D. L. (2018) · Diabetic Medicine · doi:10.1111/dme.13791 · Cited by 4
Zaki, A. M., Abo‐elnour, D. E., Abdalla, Y. E., Hassan, R. Y., Salama, M. K., Elboraay, T., & Abdelhaleem, I. A. (2022) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2022.102657 · Cited by 4
Zhang, W., Yu, M., & Cheng, G. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1373314 · Cited by 4
Huang, L., Hu, R., & Zou, H. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1419729 · Cited by 4
Tentolouris, A., Koufakis, T., & Fousteris, E. (2026) · Current Obesity Reports · doi:10.1007/s13679-026-00693-9 · Cited by 5
“%) and 52 weeks (−0.25% and − 0.31%; all p < 0.001) and promoted weight loss (−4.32 kg with 400 mg at 52 weeks) alongside lower insulin requirements [107].”
InfluentialNgan, J., O'Neal, D. N., Lee, M. H., Kong, Y. W., & MacIsaac, R. J. (2025) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2025.112278 · Cited by 3
Forner, P. M., SNAITH, J. R., & Greenfield, J. R. (2023) · Internal Medicine Journal · doi:10.1111/imj.16312 · Cited by 6
Zeng, X., Liu, Z., Li, H., & Liu, J.-Y. (2024) · Current Stem Cell Research & Therapy · doi:10.2174/011574888x288930240523045700 · Cited by 4
La variabilité glycémique : un facteur de risque singulier à conjuguer au pluriel
Monnier, L., Colette, C., Bonnet, F., & Owens, D. R. (2021) · Médecine des Maladies Métaboliques · doi:10.1016/j.mmm.2021.11.003 · Cited by 3
Hamaguchi, M., Yoshimura, Y., Nakajima, H., Tanaka, T., Hasegawa, G., Ishii, M., Okada, H., Mitsuhashi, K., Kitagawa, N., Okamura, T., et al. (2022) · Journal of Clinical Biochemistry and Nutrition · doi:10.3164/jcbn.22-7 · Cited by 3
Non-insulin therapies in addition to insulin in Type 1 DM treatment
Llano, A., & McKay, G. A. (2020) · British Medical Bulletin · doi:10.1093/bmb/ldaa011 · Cited by 3
van Laar, A., Gallardo‐Nuell, L., Pazmiño, S., Visser, M. M., Mertens, A. C., Vangoitsenhoven, R., Gillard, P., Al‐Ozairi, E., le Roux, C. W., Rosen, J., et al. (2025) · EClinicalMedicine · doi:10.1016/j.eclinm.2025.103589 · Cited by 4
Heart Failure in Type 1 vs. Type 2 Diabetes Mellitus: Shared Pathways, Distinct Challenges
Hussain, M. S., Iyer, S., Liew, Y. J., Win, M. L., McCrimmon, R. J., Lang, C. C., & Mordi, I. R. (2026) · Journal of Diabetes Research · doi:10.1155/jdr/7460084 · Cited by 2
“Similar bene fi ts were observed in individuals with BMI ≥ 27 kg/m 2 , suggesting Sotagli fl ozin may offer meaningful long-term cardiorenal protection in T1D [111, 112].”
Saha, S., Saha, S., & Gayen, M. (2023) · Journal of Diabetes and Metabolic Disorders · doi:10.1007/s40200-023-01192-7 · Cited by 2
Bantounou, M. A., Sardellis, P., Thuemmler, R. J., Boada, D. B., Kaczmarek, J., Mahmood, R., Plascevic, J., & Philip, S. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15364 · Cited by 4
“Eight 27,28,30 – 32”
MethodUse of Sodium-Glucose Cotransporter Inhibitors in Type 1 Diabetes: The Promise and the Perils
Peter, P. R., & Inzucchi, S. E. (2024) · Endocrine Practice · doi:10.1016/j.eprac.2024.03.022 · Cited by 3
Ngan, J., O'Neal, D. N., Lee, M. H., Kong, Y. W., & MacIsaac, R. J. (2025) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2025.112284 · Cited by 2
Chen, M.-B., Xu, R., Zheng, Q.-H., Zheng, X., Wang, H., Ding, Y., & Yue, M.-X. (2019) · Medicine · doi:10.1097/md.0000000000016850 · Cited by 2
“bring more patients to the standard.([12,13]) However, SOTA may cause kinds of serious adverse events.”
BackgroundReflections on Diabetes Care at the End of the Second Decade of the 21st Century
Garg, S. K. (2020) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2020.0014 · Cited by 2
Self-citationPetersen, M. C., Jones, K. E., Markov, A. M., Salam, M., Krutilova, P., McKee, A. M., Bohnert, K. L., Adamson, S. E., & McGill, J. B. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16324 · Cited by 1
Wang, W. T., & Loh, W. J. (2025) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000940 · Cited by 2
Omrani, M. A., Baskaran, B. S., Sadeghi, H., Ahmadi, F., Eddin, L. E., Jafari, A., & Muanda, F. T. (2026) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2026.2641874 · Cited by 2
European Association for the Study of Diabetes 2018
Kurian, M. J., Rentzepis, P. J., Carracher, A. M., & Close, K. L. (2018) · Journal of Diabetes · doi:10.1111/1753-0407.12876 · Cited by 1
Egashira, T., Ichinomiya, T., Yokoyama, A., Matsumoto, S., Higashijima, U., Sekino, M., Murata, H., Yoshitomi, O., Sato, S., & Hara, T. (2024) · Cureus · doi:10.7759/cureus.59757 · Cited by 3
“The hypoglycemic effect of SGLT2 inhibitors diminishes over time owing to compensatory reabsorption through SGLT1 [8,9], prompting the recent development of sotagliflozin, a dual SGLT1/2 inhibitor exhibiting relatively low SGLT2 selectivity of 20-fold over SGLT1, to achieve improved glycemic…”
BackgroundTan, K. C. B., Chow, W., Leung, J. Y., Ho, A. Y. Y., Ozaki, R., Kam, G. Y. W., Li, J., Choi, C. C., Tsang, M., Chan, N. N., et al. (2019) · Hong Kong Medical Journal · doi:10.12809/hkmj197802 · Cited by 2
Morales, L. F. M., & Leal, J. P. M. (2019) · Revista Medica Sinergia · doi:10.31434/rms.v4i10.281 · Cited by 1
“Fue un estudio de 52 semanas, donde se catalogó en 3 grupos a los 739 pacientes de manera randomizada (14).”
BackgroundInfluentialDapagliflozin: an effective adjunctive treatment in type 1 diabetes
Yadegarfar, G., Livingston, M. A., Cortés, G., Alshames, R., Leivesley, K., Metters, A., Horne, L., Steele, T., & Heald, A. H. (2021) · Cardiovascular Endocrinology & Metabolism · doi:10.1097/xce.0000000000000248 · Cited by 1
New Medications for the Treatment of Diabetes
Garg, S. K., & GIORDANO, D. A. (2019) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2019.2513 · Cited by 1
Self-citationFisher, M., Llano, A., & McKay, G. (2022) · Wiley eBooks · doi:10.1002/9781119785033.ch5 · Cited by 1
Reflections from the 78th Scientific Sessions of the American Diabetes Association
Day, C. (2018) · British Journal of Diabetes · doi:10.15277/bjd.2018.186
SGLT-Hemmer als therapeutische Option bei Patienten mit Typ 1 Diabetes mellitus
Sourij, C., Obermayer, A. M., & Sourij, H. (2018) · Journal für Klinische Endokrinologie und Stoffwechsel · doi:10.1007/s41969-018-0050-7
Buse, J. B. (2018) · US Endocrinology · doi:10.17925/use.2018.14.2.54
Self-citationSodium-Glucose Cotransporter 2 Inhibitors for People with Type 1 Diabetes
Kim, C. H., & Moon, J. S. (2019) · Journal of Korean Diabetes · doi:10.4093/jkd.2019.20.2.92
Metadata
- Authors
- Buse, J. B., Garg, S. K., Rosenstock, J., Bailey, T. S., Banks, P., Bode, B. W., Danne, T., Kushner, J. A., Lane, W. S., Lapuerta, P., McGuire, D. K., Peters, A. L., Reed, J., Sawhney, S., & Strumph, P.
- Affiliations
- University of North Carolina at Chapel Hill (US)
- University of Colorado Anschutz (US)
- Dallas Diabetes Research Center (US)
- AMCR Institute (US)
- Lexicon Pharmaceuticals (United States) (US)
- Emory University (US)
- Medizinische Hochschule Hannover (DE)
- Baylor College of Medicine (US)
- Mountain Diabetes and Endocrine Center (US)
- The University of Texas Southwestern Medical Center (US)
- University of Southern California (US)
- Endocrine Research Solutions (United States) (US)
- Corresponding author
- Buse, John B.
- ORCID
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2018-06-24
- Volume
- 41
- Issue
- 9
- Pages
- 1970-1980
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- PMC
- PMC6105319
- OpenAlex
- W2809153459
- Cited by
- 234
- References
- 41
- Citations by year
- 2026: 19 · 2025: 27 · 2024: 24 · 2023: 26 · 2022: 16 · 2021: 22 · 2020: 39 · 2019: 49 · 2018: 12
- FWCI
- 24.47
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Diabetes Care (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (UL1TR001111, UL1TR002489)
- National Center for Advancing Translational Sciences
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Diabetes and associated disorders
- Keywords
- sotagliflozin, type 1 diabetes, glycemic control, HbA1c, weight loss, insulin dose reduction, diabetes treatment satisfaction, genital mycotic infections, diarrhea, diabetic ketoacidosis, adults with type 1 diabetes, drug safety and efficacy
- MeSH terms
- Adult, Aged, Body Weight, Diabetes Mellitus, Type 1, Double-Blind Method, Drug Therapy, Combination, Female, Glycosides, Glycated Hemoglobin, Humans, Hypoglycemia, Insulin, Insulin Infusion Systems, Male, Middle Aged, North America, Weight Loss, Diabetic Ketoacidosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.